Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials

NEW YORK, May 16 /PRNewswire-FirstCall/ -- Pulmo BioTech Inc. (OTC
Bulletin Board: PLMO.OB) has announced details of the methodology and
purpose of its Phase I Human Trials with its PulmoBind Molecular Imaging
technology for the diagnosis of Pulmonary Embolism and Pulmonary
Hypertension.

The work will be carried out by the Pulmo BioTech subsidiary,
PulmoScience Inc., and the title of the work is: "Phase I Study of the Use
of PulmoBind for Molecular Imaging of the Pulmonary Circulation."

The study will be a single center, Phase 1 safety and efficacy study of
a single intravenous injection of PulmoBind in human subjects with no
history of lung disease.



The Outcomes will be:

1. Safety -- to determine pharmacokinetics and biodistribution of
PulmoBind in humans and to perform dosimetric evaluation

2. Efficacy -- to evaluate the ability of PulmoBind to allow lung
perfusion imaging in humans

Pulmo BioTech expects this work to be completed by late summer 2008.
About Pulmo BioTech Inc.

Pulmo BioTech Inc. specializes in the development and marketing of
medical technology and research. Our proven strengths combine extensive
commercial experience and academic credentials. The principal staff members
are acknowledged experts in their specialized fields, and work with a broad
range of investment institutions. Pulmo BioTech's mission is to utilize
scientific imagination and drive, together with managerial and financial
acumen, to bring innovative and profitable products to the marketplace to
the benefit of all stock holders.

About PulmoScience Inc.

PulmoScience Inc. was established in 2006, and is currently developing
a non-invasive Molecular Imaging technique for the diagnosis of Pulmonary
Embolism, Pulmonary Hypertension and Lung Inflammatory diseases under the
trade name PulmoBind.

The company was conceived within the Montreal Heart Institute "MHI" (a
world renowned hospital and educational facility). Jointly owned by MHI
subsidiary Innovacor as the technical and operational partner, Dr. Jocelyn
Dupuis (the scientific director and originator of the PulmoBind Molecular
Imaging technology), and by Pulmo BioTech Inc. as the funding partner,
PulmoScience Inc. aims to develop this unique and exciting technology, to
fund necessary trials, and to bring the products to market.

PulmoScience believes that the market for its product candidates is
worth in excess of $500 million per annum and that, provided Regulatory
Approval is achieved, the safety and efficacy of its products could allow
it to dominate that market.

About PulmoBind

PulmoBind uses an intravenously delivered radionuclide tagged molecule
which specifically bonds to the inner walls of the circulatory system in
the lungs, and by the use of an external Gamma Camera allows an image of
the integrity of the blood vessels throughout the lungs to be seen by a
diagnostic clinician. PulmoScience is currently undertaking Regulatory
Approval for Phase I Human Trials, and while subsequent results from
additional tests might not corroborate the current results, PulmoScience
believes that PulmoBind has the potential to dominate the market for the
diagnosis of Pulmonary Embolism. In particular, this belief is driven by
PulmoScience's expectations of the improved safety and efficacy that
PulmoBind will offer when compared to the current incumbent nuclear
medicine based technology for the diagnosis of Pulmonary Embolism. In
addition, early indications are that PulmoBind could be highly effective in
the early stage diagnosis of Pulmonary Hypertension, a condition for which
there is no current front line diagnostic test.

Forward-Looking Statements

Forward-looking statements contained in this and other written and oral
reports are made based on known events and circumstances at the time of
release, and as such, are subject in the future to unforeseen uncertainties
and risks. All statements regarding future performance, earnings
projections, regulatory approval, events or developments are
forward-looking statements. It is possible that the future performance of
the company may differ materially from current expectations, depending on
economic conditions and the uncertainty of regulatory approval. A change in
economic conditions may have a particularly volatile effect on results.
Among the other factors which may affect future performance are:
competitive market conditions and resulting effects on sales and pricing;
increases in raw-material costs that cannot be recovered in product
pricing; and global economic factors, including difficulties entering new
markets and general economic conditions such as inflation, interest rates
and credit availability. The company makes these statements as of the date
of this disclosure, and undertakes no obligation to update them.





See Also

• LocumTenens.com Joins Give an Hour in Supporting U.S. Military Troops
• Physician Survey Reveals that Universal Healthcare Will Intensify the U.S. Doctor Shortage: LocumTenens.com Says That 20 Percent of Physicians Will Leave Medicine
• GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)
• Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes

Via: Healthcare